. . . . . . . "[Although Bortezomib increased the levels of p53 and increased the expression of pro-apoptotic target genes in ER?+ breast cancer cells harboring wild-type p53, Bortezomib also exerts anti-tumoral effects on ER?+ breast cancer cells through suppression of ER? expression and inhibition of PI3K/Akt/mammalian target of rapamycin (mTOR) and ERK signaling independently of functional p53.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:17:00+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .